Developer docs
API playgroundTry for free, no card

Search company profiles

BTG International

Full company profile

uuid0006btp

Namestring
BTG International
Legal namestring
Boston Scientific Corporation
Websiteurl
btgplc.com
Company typeenum
Public
Founded yearint
1948
Descriptiontext

BTG International is a global healthcare company focused on interventional medicine, founded in 1948 and headquartered in London, United Kingdom. The company develops, manufactures, and commercializes medical devices and specialty pharmaceuticals used by interventional specialists across vascular, oncology, pulmonology, urology, and pain management. Its portfolio has been built substantially through acquisition, with eight disclosed transactions between 2005 and 2018 — including EKOS (ultrasound-assisted thrombolysis, 2013, ~$220M), PneumRx (lung volume reduction coils, 2014, ~$475M), Galil Medical (cryoablation, 2016, ~$110M), Biocompatibles International (drug-eluting embolic beads, 2010, ~$242M), and Protherics (specialty biopharmaceuticals/antidotes, 2008, ~$397M) — alongside smaller undisclosed bolt-ons such as Roxwood Medical (2017) and Novate Medical (2018).

The company's commercial model is a regulated medical device and specialty pharma go-to-market: it sells to hospitals, interventional radiologists, vascular surgeons, urologists, pulmonologists, and oncology centers globally, with an installed workforce of 1001-5000 employees supporting international sales, clinical education, and regulatory affairs. Pricing details are not publicly disclosed, consistent with typical med-tech B2B contracting through hospital procurement, GPOs, and reimbursement pathways. Leadership includes Founder Phillip Breech, CFO Duncan Kennedy, Chief Development Officer Jamie Heath, and General Manager Steve Baldwin, reflecting a functional operating structure spanning finance, product development, and commercial operations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMarlborough, United States
HQ citystring
Marlborough
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
interventional medicine, interventional radiology, vascular therapy, medical device manufacturing, specialty pharmaceuticals
Industry1 code
PRIMARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Diagnostic Imaging Centers621512
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • X-Ray Apparatus & Tubes & Related Irradiation Apparatus3844
Product category
Interventional Medicine Devices
Social media profiles1 record
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BTG International is a global healthcare company focused on Interventional Medicine, developing and commercializing medical devices and specialty pharmaceuticals used in minimally invasive procedures. The company's portfolio spans interventional oncology, vascular, and pulmonary therapies acquired through targeted M&A (including EKOS ultrasound-assisted thrombolysis, Galil Medical cryoablation, PneumRx lung coils, and Novate Medical IVC filters). Operations are headquartered in London, United Kingdom, with the entity now operating as part of Boston Scientific Corporation.

Differentiator
Functional benefit
Problem solved
Product and service8 records
1EKOS Ultrasound-Assisted Thrombolysis System
CategoryVascular Intervention
Description

Medical device for ultrasound-assisted catheter-directed thrombolysis in patients with vascular thrombosis, used by interventional radiologists and vascular specialists.

2Galil Medical Cryoablation Systems
CategoryInterventional Oncology
Description

Cryoablation medical devices for minimally invasive tumor destruction, used by interventional radiologists and oncologists.

3PneumRx Lung Coils
CategoryPulmonary Intervention
Description

Medical device portfolio targeting pulmonary intervention in emphysema/lung disease, used by interventional pulmonologists.

4Biocompatibles Drug-Eluting Beads
CategoryInterventional Oncology
Description

Drug-eluting bead technology for transarterial chemoembolization used in interventional oncology, primarily for liver cancer treatment.

5Protherics Specialty Pharmaceuticals
CategorySpecialty Pharmaceuticals
Description

Specialty pharmaceutical products used as antidotes/therapies in interventional and acute care settings, serving hospitals and emergency care providers.

6Novate Medical IVC Filter
CategoryVascular Intervention
Description

Inferior vena cava (IVC) filter medical device for pulmonary embolism prevention, used by vascular intervention specialists.

7Roxwood Medical Vascular Devices
CategoryVascular Intervention
Description

Vascular intervention medical devices used by interventional radiologists and vascular surgeons.

8CellMed AG Products
CategoryInterventional Medicine
Description

Cell therapy/biomedical products integrated into the interventional medicine portfolio.

Partnership1 partner
TypeStrategic or Co-development PartnerAnnounced on2024-06-01
Description

In June 2024, AstraZeneca Plc completed its acquisition of Fusion Pharmaceuticals Inc. for $2.5 billion to strengthen its radiopharmaceutical portfolio. This acquisition represents a significant strategic move in the radiopharmaceutical space for cancer treatment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AngioDynamics is a US-based interventional medical device company with overlapping product lines in ablation, embolization (embolic beads), and vascular access. Its oncology-focused NanoKnife and bead products compete directly with BTG's interventional oncology portfolio in similar hospital call points.

TypeBroad incumbent
Description

Stryker operates interventional and surgical device franchises (neurovascular, spine, ENT, surgical instruments). It competes with several BTG product lines through overlapping hospital specialty call points and serves a similar procedural specialist base.

TypeEmerging player
Description

Inari Medical is a high-growth pure-play in venous thromboembolism intervention (FlowTriever, ClotTriever), directly competing with BTG's EKOS catheter-directed thrombolysis in the PE and DVT markets. Both target interventional cardiologists, vascular surgeons, and IRs treating venous disease.

TypeBroad incumbent
Description

Boston Scientific acquired BTG International in 2019 for ~$4.2B and is now the corporate parent. BSX operates an overlapping interventional medicine portfolio (peripheral intervention, endoscopy, neuromodulation, urology) and provides the commercial scale on which BTG's products now ride.

TypeDirect peer
Description

Sirtex is the most direct competitor to BTG's TheraSphere franchise, offering SIR-Spheres Y-90 resin microspheres for radioembolization of liver tumors. Both compete head-to-head in interventional oncology with comparable modalities, targeting the same hepatic oncology indications and specialist physician base.

TypeDirect peer
Description

Penumbra develops interventional thrombectomy and embolization devices for stroke, peripheral vascular disease and venous thromboembolism. Its peripheral thrombectomy portfolio directly overlaps with BTG's EKOS ultrasound-assisted thrombolysis franchise, and both target the same interventional radiology and vascular surgery call points.

TypeDirect peer
Description

Merit Medical manufactures single-use interventional devices including embolization particles, microcatheters, and oncology ablation tools that compete with BTG's LC Bead embolics and other interventional consumables. Both serve interventional radiologists globally through hospital purchasing channels.

TypeBroad incumbent
Description

Medtronic operates a large interventional portfolio including neurovascular, peripheral vascular, and oncology ablation devices. As a broad incumbent in interventional medicine, it competes with several BTG product lines (peripheral intervention, embolization) across the same hospital specialty channels.

TypeBroad incumbent
Description

Novartis, through its Advanced Accelerator Applications subsidiary and Pluvicto (Lu-177 PSMA-617) radioligand therapy, is the dominant force in therapeutic radiopharmaceuticals. It competes with BTG's TheraSphere Y-90 franchise for oncology budgets, though in adjacent (radioligand vs. radioembolization) modalities rather than identical indications.

TypeDirect peer
Description

Teleflex provides interventional access, vascular, and specialty pharmaceutical products, including catheter-based therapies that overlap with BTG's interventional portfolio. Both companies serve interventional radiology and vascular surgery customers through similar hospital supply channels.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment8 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BTG International

Interventional Medicine Devicesbtgplc.com

What BTG International does

BTG International is a global healthcare company focused on interventional medicine, founded in 1948 and headquartered in London, United Kingdom. The company develops, manufactures, and commercializes medical devices and specialty pharmaceuticals used by interventional specialists across vascular, oncology, pulmonology, urology, and pain management. Its portfolio has been built substantially through acquisition, with eight disclosed transactions between 2005 and 2018 — including EKOS (ultrasound-assisted thrombolysis, 2013, ~$220M), PneumRx (lung volume reduction coils, 2014, ~$475M), Galil Medical (cryoablation, 2016, ~$110M), Biocompatibles International (drug-eluting embolic beads, 2010, ~$242M), and Protherics (specialty biopharmaceuticals/antidotes, 2008, ~$397M) — alongside smaller undisclosed bolt-ons such as Roxwood Medical (2017) and Novate Medical (2018).

The company's commercial model is a regulated medical device and specialty pharma go-to-market: it sells to hospitals, interventional radiologists, vascular surgeons, urologists, pulmonologists, and oncology centers globally, with an installed workforce of 1001-5000 employees supporting international sales, clinical education, and regulatory affairs. Pricing details are not publicly disclosed, consistent with typical med-tech B2B contracting through hospital procurement, GPOs, and reimbursement pathways. Leadership includes Founder Phillip Breech, CFO Duncan Kennedy, Chief Development Officer Jamie Heath, and General Manager Steve Baldwin, reflecting a functional operating structure spanning finance, product development, and commercial operations.

BTG International firmographics

Firmographics
Name
BTG International
Legal name
Boston Scientific Corporation
Website
https://btgplc.com
Company type
Public
Founded year
1948
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

BTG International industry classification

Industry
Product category
Interventional Medicine Devices
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Diagnostic Imaging Centers (621512)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)
akta.pro industry
PRIMARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • Interventional medicine
  • Interventional radiology
  • Vascular therapy
  • Medical device manufacturing
  • Specialty pharmaceuticals

Where BTG International is headquartered

Location

Headquarters

HQ city
Marlborough
HQ country
United States
HQ region
North America

Markets served

BTG International business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

BTG International product offering

Product offering

Core offering

BTG International is a global healthcare company focused on Interventional Medicine, developing and commercializing medical devices and specialty pharmaceuticals used in minimally invasive procedures. The company's portfolio spans interventional oncology, vascular, and pulmonary therapies acquired through targeted M&A (including EKOS ultrasound-assisted thrombolysis, Galil Medical cryoablation, PneumRx lung coils, and Novate Medical IVC filters). Operations are headquartered in London, United Kingdom, with the entity now operating as part of Boston Scientific Corporation.

Differentiator

Problem solved

Functional benefit

Products and services

  • EKOS Ultrasound-Assisted Thrombolysis System Medical device for ultrasound-assisted catheter-directed thrombolysis in patients with vascular thrombosis, used by interventional radiologists and vascular specialists.
  • Galil Medical Cryoablation Systems Cryoablation medical devices for minimally invasive tumor destruction, used by interventional radiologists and oncologists.
  • PneumRx Lung Coils Medical device portfolio targeting pulmonary intervention in emphysema/lung disease, used by interventional pulmonologists.
  • Biocompatibles Drug-Eluting Beads Drug-eluting bead technology for transarterial chemoembolization used in interventional oncology, primarily for liver cancer treatment.
  • Protherics Specialty Pharmaceuticals Specialty pharmaceutical products used as antidotes/therapies in interventional and acute care settings, serving hospitals and emergency care providers.
  • Novate Medical IVC Filter Inferior vena cava (IVC) filter medical device for pulmonary embolism prevention, used by vascular intervention specialists.
  • Roxwood Medical Vascular Devices Vascular intervention medical devices used by interventional radiologists and vascular surgeons.
  • CellMed AG Products Cell therapy/biomedical products integrated into the interventional medicine portfolio.

Companies that use BTG International

Customer profile

Ideal customer profiles2 records

BTG International technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BTG International partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Fusion Pharmaceuticals Inc.Strategic or Co-development Partner · 1 June 2024In June 2024, AstraZeneca Plc completed its acquisition of Fusion Pharmaceuticals Inc. for $2.5 billion to strengthen its radiopharmaceutical portfolio. This acquisition represents a significant strategic move in the radiopharmaceutical space for cancer treatment.

Recent moves6 records

Expansion highlights4 records

BTG International competitors and assessment

Company assessment

Direct peers

  • AngioDynamics: AngioDynamics is a US-based interventional medical device company with overlapping product lines in ablation, embolization (embolic beads), and vascular access. Its oncology-focused NanoKnife and bead products compete directly with BTG's interventional oncology portfolio in similar hospital call points.
  • Sirtex Medical: Sirtex is the most direct competitor to BTG's TheraSphere franchise, offering SIR-Spheres Y-90 resin microspheres for radioembolization of liver tumors. Both compete head-to-head in interventional oncology with comparable modalities, targeting the same hepatic oncology indications and specialist physician base.
  • Penumbra, Inc. Penumbra develops interventional thrombectomy and embolization devices for stroke, peripheral vascular disease and venous thromboembolism. Its peripheral thrombectomy portfolio directly overlaps with BTG's EKOS ultrasound-assisted thrombolysis franchise, and both target the same interventional radiology and vascular surgery call points.
  • Merit Medical Systems: Merit Medical manufactures single-use interventional devices including embolization particles, microcatheters, and oncology ablation tools that compete with BTG's LC Bead embolics and other interventional consumables. Both serve interventional radiologists globally through hospital purchasing channels.
  • Teleflex Incorporated: Teleflex provides interventional access, vascular, and specialty pharmaceutical products, including catheter-based therapies that overlap with BTG's interventional portfolio. Both companies serve interventional radiology and vascular surgery customers through similar hospital supply channels.

Broad incumbents

  • Stryker Corporation: Stryker operates interventional and surgical device franchises (neurovascular, spine, ENT, surgical instruments). It competes with several BTG product lines through overlapping hospital specialty call points and serves a similar procedural specialist base.
  • Boston Scientific Corporation: Boston Scientific acquired BTG International in 2019 for ~$4.2B and is now the corporate parent. BSX operates an overlapping interventional medicine portfolio (peripheral intervention, endoscopy, neuromodulation, urology) and provides the commercial scale on which BTG's products now ride.
  • Medtronic plc: Medtronic operates a large interventional portfolio including neurovascular, peripheral vascular, and oncology ablation devices. As a broad incumbent in interventional medicine, it competes with several BTG product lines (peripheral intervention, embolization) across the same hospital specialty channels.
  • Novartis AG (Advanced Accelerator Applications / Pluvicto): Novartis, through its Advanced Accelerator Applications subsidiary and Pluvicto (Lu-177 PSMA-617) radioligand therapy, is the dominant force in therapeutic radiopharmaceuticals. It competes with BTG's TheraSphere Y-90 franchise for oncology budgets, though in adjacent (radioligand vs. radioembolization) modalities rather than identical indications.

Emerging players

  • Inari Medical: Inari Medical is a high-growth pure-play in venous thromboembolism intervention (FlowTriever, ClotTriever), directly competing with BTG's EKOS catheter-directed thrombolysis in the PE and DVT markets. Both target interventional cardiologists, vascular surgeons, and IRs treating venous disease.

Market position

Weaknesses4 records

Competitive moat3 records

Customer concentration

BTG International social profiles

Digital presence

BTG International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BTG International leadership team

Management profile

Number of profiles

Profiles4 records

BTG International funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BTG International M&A and investment

M&A and investment

M&A9 records

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BTG International

What does BTG International do?

BTG International is a global healthcare company focused on Interventional Medicine, developing and commercializing medical devices and specialty pharmaceuticals used in minimally invasive procedures. The company's portfolio spans interventional oncology, vascular, and pulmonary therapies acquired through targeted M&A (including EKOS ultrasound-assisted thrombolysis, Galil Medical cryoablation, PneumRx lung coils, and Novate Medical IVC filters). Operations are headquartered in London, United Kingdom, with the entity now operating as part of Boston Scientific Corporation.

Is BTG International a public or private company?

BTG International is a public company. It is classified as corporate owned and is currently operating.

When was BTG International founded?

BTG International was founded in 1948. It employs 1,001 to 5,000 people.

Where is BTG International based?

BTG International is headquartered in Marlborough, United States, in the North America region.

Who are BTG International's main competitors?

Direct peers on record are AngioDynamics, Sirtex Medical, Penumbra, Inc., Merit Medical Systems and Teleflex Incorporated. Broad incumbents are Stryker Corporation, Boston Scientific Corporation, Medtronic plc and Novartis AG (Advanced Accelerator Applications / Pluvicto). Inari Medical is listed as an emerging player.

Does BTG International have an API?

No public API is recorded for BTG International.

What industry is BTG International in?

BTG International's product category is Interventional Medicine Devices. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal Varicose Vein Treatment IndustryA market research report projects the global varicose vein treatment industry will grow by US$174.3 Million with a compounded annual growth rate of 5.5%, driven largely by the Injection Sclerotherapy segment. The study highlights significant regional opportunities, particularly in China which is expected to add approximately US$47.1 Million in addressable opportunity, while also detailing forecasts for the United States, Europe, and Japan. Key competitors identified in this expanding market include AngioDynamics, biolitec AG, BTG PLC, Medtronic PLC, and others.Worcester Business JournalBoston Scientific closes $4B acquisition of U.K. firm BTGBoston Scientific closed its $4-billion acquisition of U.K. cancer firm BTG, gaining access to its international medicine portfolio including oncology treatments for liver and kidney cancers. The company plans to sell the royalty and licensing arrangements for BTG's prostate cancer drug Zytiga, expected to close by year-end.News-MedicalPrice of snakebite drug is sky high, but new competitor unlikely to lower costsCroFab, a snake antivenin, costs $3,198 per vial, while the new competitor Anavip is priced at $1,220 per vial. Despite competition, patent royalties and regulatory hurdles prevent meaningful price reductions. BTG plans to maintain market dominance without lowering CroFab's price.NPRWhy Competition Hasn't Brought Down The High Price Of Snakebite TreatmentSnake antivenin CroFab, priced at $3,198 per vial, faces competition from Anavip at $1,220 per vial, but legal and regulatory barriers prevent meaningful price cuts. BTG, CroFab's maker, plans to maintain dominance through patent strategies and formula improvements.This is MoneyBTG chief Dame Louise Makin in line for £20m windfall after firm's saleBTG's sale to Boston Scientific for £3.3b could give boss Dame Louise Makin up to £20m in bonuses, shares, and performance pay. The US firm offered 840p a share, 37% above BTG's closing price of 615p, and shares have since risen 34% to 826p.PR NewswireDennis and Mireille Gillings Foundation Donation Unites Funders for £1.35M Programme to Develop a New Generation of Leaders in Medical ScienceThe Academy of Medical Sciences has launched the Future Leaders in Innovation, Enterprise and Research (FLIER) programme, supported by a £600,000 pledge from the Dennis and Mireille Gillings Foundation and a £750,000 commitment from the UK Government. The two-year initiative aims to train emerging leaders in biomedical and health research to foster collaboration across academia, industry, and the NHS. Companies including GSK, BTG International, and BenevolentAI were involved in scoping the programme.BloombergHow Blankfein Inspired BTG’s CEO to Try Out Social MediaBTG CEO Roberto Sallouti cited Lloyd Blankfein's social media use as inspiration to rebuild the bank's brand after the Esteves crisis. He said BTG aims to be a 'faceless' institution, using social media to be more open and reach clients directly.The TelegraphDrugmaker BTG bets on devices to help treat cancerBTG is investing £500,000 into R&D to trial medical devices that deliver immune-boosting cancer drugs directly to tumors. The company aims to avoid systemic side effects from current oral therapies. It is in discussions with larger pharmaceutical rivals for potential partnerships.MedCity NewsWill digital health’s impact in pharma mean that size will matter less?At Health 2.0 Fall, BTG's Amanda Goltz argued that smaller specialty pharma firms can be more agile in digital health, citing its cancer patient app and collaboration with Tonic Health. Panelists like Bayer's Eugene Borukhovich emphasized that digital health success depends on patient-clinician partnerships, not just technology.PE HubBTG buys cryoablution company Galil for $84.5 mlnBTG plc agreed to acquire Galil Medical for an initial $84.5 million cash payment, with up to $25.5 million in future payments through 2018. Galil provides cryoablution therapies for oncological treatment. The deal was advised by multiple firms, including Houlihan Lokey and Willkie Farr.